Taylor Alison Swift is an American singer-songwriter. She is known for narrative songs about her personal life, which have received widespread media coverage. At age 14, Swift became the youngest artist signed by the Sony/ATV Music publishing house and, at 15, she signed her first record deal.
Her 2006 eponymous debut album was the longest-charting album of the 2000s in the US. Its third single, "Our Song", made her the youngest person to single-handedly write and perform a number-one song on the Billboard Hot Country Songs chart. Swift's second album, Fearless, was released in 2008.
Buoyed by the pop crossover success of the singles "Love Story" and "You Belong with Me", it became the US' best-selling album of 2009 and was certified diamond in the US. The album won four Grammy Awards, and Swift became the youngest Album of the Year winner.
New eczema drug therapy 'highly effective' for young children
dailyrecord.co.ukA new drug therapy for young children who suffer with "moderate to severe" eczema has been proven to work well during clinical trials.
The drug therapy, called dupilumab, reportedly improved the severity of the skin condition within just two weeks. Based on the results, which were published in the international medical journal The Lancet, the treatment may soon be approved in the UK for children under six years old.
The drug therapy has already been approved in the US, and has been since June this year. It's also already licenced in the UK for adults and children aged six to 18.In the study, the children were all aged from six months to six years old, and it was found their condition significantly approved.
The children and their parents also reported better sleep, and a "better quality of life" overall.Dr Peter Arkwright, from the University of Manchester, who is principle investigator for the Manchester arm of the trial, said: "Young children and infants who have moderate to severe eczema have a substantially reduced quality of life."It’s also incredibly stressful for their families, particularly as children’s sleep is so disturbed."The fact that infants and young children with moderate to severe eczema are inadequately controlled with creams means they have a high unmet medical need."We’re so delighted that dupilumab has provided clinically meaningful improvement, with an acceptable safety profile."These pivotal trial results strongly support the global approval of dupilumab in infants and children with eczema."It will revolutionise clinical practice worldwide."Eczema is a condition that causes the skin to become itchy, dry and cracked.It is more common in children, often developing before they turn one, and is
Read more on dailyrecord.co.uk